Articles related to CLINICAL TRIALS

A 2019 trial report from NEJM offered a comparative analysis of levetiracetam, fosphenytoin, and valproate in managing benzodiazepine-resistant convulsive status epilepticus, providing essential insights into their efficacy and safety, aiding clinicians in informed decision-making.

Explore new horizons in advanced hepatocellular carcinoma treatment with emerging data on lenvatinib and cisplatin’s potential efficacy as a second-line therapy and the promising triple combination therapy showing significant response rates.

Explore the latest insights from ASCO GU 2024 on first-line treatments for advanced renal cell carcinoma, including the effectiveness of combination therapies and the pressing need to address racial disparities in patient outcomes.

Mirvetuximab soravtansine represents a pivotal shift in treating platinum-resistant ovarian cancer, demonstrating not only improved survival outcomes but also a higher response rate compared to standard chemotherapy.

In a recent phase 3 trial, the addition of brentuximab vedotin to standard chemotherapy not only achieved a notable improvement in 3-year event-free survival rates for pediatric Hodgkin’s lymphoma patients but also maintained a comparable safety profile, underscoring the therapeutic potential of targeted treatments in this population.

The combination of ribociclib and a nonsteroidal aromatase inhibitor was associated with a notable improvement in invasive disease–free survival rates among early-stage, HR-positive, HER2-negative breast cancer patients, highlighting a significant advancement in the therapeutic landscape of this common malignancy.